

**Certificate of Analysis** 

# Ludger-BioQuant<sup>™</sup> GPEP A2G2S2 Glycopeptide Standard

Cat. #: BQ-GPEP-A2G2S2-10U Size: 10 μg (3.49nmol)

Batch: B888-03 Expiry Date: 09 Aug 2023

# **Glycan Structure**



The glycopeptide is comprised of an A2G2S2 glycan attached to the asparagine amino acid of a peptide with the sequence Lysine-Valine-Alanine-Asparagine-Lysine-Threonine (KVANKT).

Glycan Purity determined as > 95% by UHPLC.

Monoisotopic mass: 2865.1763 [M+H]+

Storage conditions: -20°C

# BQ-GPEP-A2G2S2-10U Quantity Summary

The amount of GPEP-A2G2S2 glycopeptide to be dispensed per vial is determined by quantitative Nuclear Magnetic Resonance (qNMR) of the bulk glycopeptide stock. Once dispensed the **amount of glycopeptide per vial** is determined by monosaccharide analysis and sialic acid analysis. These determinations are detailed on the following pages, but a summary is provided below:

#### Amount of BQ-GPEP-A2G2S2-10U per vial

Monosaccharide based determination (GlcN – HCI hydrolysis)	=	10.08 μg ± 0.42 (3.52nmol)
Sialic acid based determination	=	9.39 ± 1.1 (3.29 nmol)



## Quantitative Nuclear Magnetic Resonance (qNMR)



Figure 1. <sup>1</sup>H-NMR (500 MHz) of BQ-GPEP-A2G2S2-Bulk in D<sub>2</sub>O (Batch Number: B87P-02)

Sample	Concentration (mM) calculated using a certified quantitative standard
BQ-GPEP-A2G2S2-Bulk	0.1906 ± 0.0038

Table 1. Concentration of BQ-GPEP-A2G2S2-Bulk calculated by qNMR

The concentration of the BQ-GPEP-A2G2S2 stock was calculated by qNMR by comparison to a certified quantitative standard (Table 1). This value was used to determine the amount of sample to be dispensed to obtain 10 µg of glycopeptide per vial.

## Monosaccharide analysis of BQ-GPEP-A2G2S2-10U

Quantitative monosaccharide analysis using the Ludger LT-MONO-96 kit was performed on 5 replicates of BQ-GPEP-A2G2S2 using 6M hydrochloric acid hydrolysis (HCI) to release the N-acetylglucosamine (GlcNAc – hydrolysed to GlcN) constituents of the glycopeptide. The GlcN monosaccharides were labelled with 2-aminobenzoic acid and chromatography was performed on a UHPLC equipped with a LudgerSep R2 monosaccharide analysis column (LS-R2-4.6x150).





The ManN monosaccharide is due to epimerisation of the GlcN monosaccharide during sample processing.

### Calculation of the amount of GPEP-A2G2S2 using the GlcN value:

#### Quantity of GlcN per vial = 14.08 ± 0.58 nmol

Quantity of BQ-GPEP-A2G2S2-10U per vial (determined by GlcN content) = 10.08 ± 0.42µg (3.52 nmol)

## Sialic acid analysis of BQ-GPEP-A2G2S2-10U

Quantitative sialic acid analysis was performed on 3 separate vials of BQ-GPEP-A2G2S2-10U using the LudgerTag<sup>™</sup> DMB sialic acid labelling kit (LT-KDMB-A1). The labelled sialic acid chromatography was performed on a UHPLC equipped with a LudgerSep uR2 column (LS-UR2-2.1x100).



Figure 3. LudgerSep-uR2 HPLC profile of 1,2-diamino-4,5-methylenedioxybenzene.2HCl (DMB) labelled Neu5Ac of acetic acid hydrolysed BQ-GPEP-A2G2S2-10U (Batch B888-03).

#### Quantity of NeuAc per vial = $6.57 \pm 0.77$ nmol

Quantity of BQ-GPEP-A2G2S2-10U per vial (determined by NeuAc content) = 9.39 ± 1.1 (3.29 nmol)



## Glycopeptide Purity and Identity of BQ-GPEP-A2G2S2-10U





Figure 5. Positive ion ESI mass spectrum of BQ-GPEP-A2G2S2-10U (Batch B888-03). KVANKT-A2G2S2 theoretical mass: 2865.18 Da